A multidisciplinary team of scleroderma specialists developed a framework for a comprehensive and sustainable approach to treating scleroderma.
Researchers investigated whether 8% silver-fiber gloves reduced the burden of Raynaud phenomenon in patients with scleroderma.
In preclinical studies, efzofitimod was found to prevent inflammation and fibrosis in multiple animal models of systemic sclerosis and idiopathic pulmonary fibrosis.
Could matrix metalloproteinase-7 serve as a biomarker for predicting the course of systemic sclerosis-linked interstitial lung disease?
Authors of a systematic review evaluated available literature assessing the role of ultrasound and elastography in skin involvement in systemic sclerosis.
Researchers evaluated the association between forced vital capacity decline and hospitalization events in patients with systemic sclerosis-associated interstitial lung disease.
The Scleroderma Foundation recently changed their name to the National Scleroderma Foundation to better inform the organization’s scope and work in the community.
Researchers explored the impact of elicitation of patient preferences in informing design, enrollment, and modifiable aspects of treatment in future randomized controlled trials.
Researchers studied the causes and predictors of acute hospitalization and in-patient mortality in patients with systemic sclerosis (SSc).
Do gastroprotective and promotility agents prevent incident interstitial lung disease in patients with systemic sclerosis?